Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Operating Income (2019 - 2023)

Historic Operating Income for ADC Therapeutics (ADCT) over the last 5 years, with Q3 2023 value amounting to -$36.1 million.

  • ADC Therapeutics' Operating Income fell 106085.42% to -$36.1 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$10.9 billion, marking a year-over-year decrease of 951947.65%. This contributed to the annual value of $4950.0 for FY2022, which is 10189.13% up from last year.
  • According to the latest figures from Q3 2023, ADC Therapeutics' Operating Income is -$36.1 million, which was down 106085.42% from -$39.6 million recorded in Q2 2023.
  • ADC Therapeutics' Operating Income's 5-year high stood at -$43.88 during Q1 2020, with a 5-year trough of -$10.7 billion in Q4 2022.
  • In the last 5 years, ADC Therapeutics' Operating Income had a median value of -$39.6 million in 2023 and averaged -$660.1 million.
  • Per our database at Business Quant, ADC Therapeutics' Operating Income surged by 9984.04% in 2020 and then plummeted by 16102302863.17% in 2021.
  • Over the past 5 years, ADC Therapeutics' Operating Income (Quarter) stood at -$35732.0 in 2019, then soared by 99.85% to -$52.43 in 2020, then plummeted by 119647.08% to -$62781.0 in 2021, then crashed by 17103800.86% to -$10.7 billion in 2022, then skyrocketed by 99.66% to -$36.1 million in 2023.
  • Its last three reported values are -$36.1 million in Q3 2023, -$39.6 million for Q2 2023, and -$51.6 million during Q1 2023.